ArticleInvestigational new drugs2026

A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer.

Fengting Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.